ICLUSIG Drug Patent Profile

When do Iclusig patents expire, and what generic alternatives are available?

Iclusig is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and nine patent family members in twenty-four countries.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ponatinib hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Iclusig

Iclusig was eligible for patent challenges on December 14, 2016.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (ponatinib hydrochloride), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for ICLUSIG

International Patents:	109
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	50
Clinical Trials:	26
Patent Applications:	1,232
Drug Prices:	Drug price information for ICLUSIG
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ICLUSIG
What excipients (inactive ingredients) are in ICLUSIG?	ICLUSIG excipients list
DailyMed Link:	ICLUSIG at DailyMed

See drug prices for ICLUSIG

Recent Clinical Trials for ICLUSIG

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Assistance Publique - Hpitaux de Paris	PHASE2
University of Chicago	Phase 2
CZECRIN - Czech Clinical Research Infrastructure Network	Phase 2

See all ICLUSIG clinical trials

Pharmacology for ICLUSIG

Drug Class	Kinase Inhibitor
Mechanism of Action	Protein Kinase Inhibitors

Paragraph IV (Patent) Challenges for ICLUSIG

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ICLUSIG	Tablets	ponatinib hydrochloride	10 mg and 30 mg	203469	1	2022-12-12
ICLUSIG	Tablets	ponatinib hydrochloride	15 mg and 45 mg	203469	1	2021-03-31

US Patents and Regulatory Information for ICLUSIG

ICLUSIG is protected by seventeen US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	ICLUSIG	ponatinib hydrochloride	TABLET;ORAL	203469-003	Apr 23, 2015		RX	Yes	No			Y	Y
Takeda Pharms Usa	ICLUSIG	ponatinib hydrochloride	TABLET;ORAL	203469-003	Apr 23, 2015		RX	Yes	No				Y
Takeda Pharms Usa	ICLUSIG	ponatinib hydrochloride	TABLET;ORAL	203469-002	Dec 14, 2012		RX	Yes	No			Y	Y
Takeda Pharms Usa	ICLUSIG	ponatinib hydrochloride	TABLET;ORAL	203469-003	Apr 23, 2015		RX	Yes	No			Y	Y
Takeda Pharms Usa	ICLUSIG	ponatinib hydrochloride	TABLET;ORAL	203469-001	Dec 14, 2012		RX	Yes	No
Takeda Pharms Usa	ICLUSIG	ponatinib hydrochloride	TABLET;ORAL	203469-004	Dec 18, 2020		RX	Yes	Yes

International Patents for ICLUSIG

When does loss-of-exclusivity occur for ICLUSIG?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

Chile

China

Hong Kong

Japan

Mexico

New Zealand

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ICLUSIG around the world.

Country	Patent Number	Title	Estimated Expiration
China	101490053
Japan	2026010061	３－（イミダゾ［１，２－ｂ］ピリダジン－３－イルエチニル）－４－メチル－Ｎ－｛４－［（４－メチルピペラジン－１－イル）メチル］－３－（トリフルオロメチル）フェニル｝ベンズアミドおよびその一塩酸塩の結晶形
Denmark	2495016
Luxembourg	92327
Australia	2019240721
Japan	2015147796	二環式ヘテロアリール化合物 (BICYCLIC HETEROARYL COMPOUNDS)

Supplementary Protection Certificates for ICLUSIG

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1973545	151 5025-2013	Slovakia		(93) EU/1/13/839/001, EU/1/13/839/002, EU/1/13/839/003, EU/1/13/839/004, 1.7.2013, EU (94) 3.7.2028
1973545	SPC/GB13/077	United Kingdom		PRODUCT NAME: PONATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT, SOLVATE OR HYDRATE THEREOF; REGISTERED: UK EU/1/13/839/001 20130703; UK EU/1/13/839/002 20130703; UK EU/1/13/839/003 20130703; UK EU/1/13/839/004 20130703
1973545	72/2013	Austria		PRODUCT NAME: PONATINIB; REGISTRATION NO/DATE: EU/1/13/839 20130701
1973545	122013000152	Germany		PRODUCT NAME: PONATINIB "BENZAMID, 3-(2-IMIDAZO(1,2-B)PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-(4-((4-METHYL-1-PIPERAZINYL)METHYL)-3-(TRIFLUORMETHYL)PHENYL)"; REGISTRATION NO/DATE: EU/1/13/839/001-004 20130701
1973545	92327	Luxembourg		PRODUCT NAME: PONATINIB SOUS TOUTES SES FORMES TELLES QUE PROTEGEES PAR LE BREVET DE BASE
1973545	PA2013027,C1973545	Lithuania		PRODUCT NAME: PONATINIBUM; REGISTRATION NO/DATE: EU/1/13/839/001, 2013 07 03 EU/1/13/839/002, 2013 07 03 EU/1/13/839/003, 2013 07 03 EU/1/13/839/004 20130703

ICLUSIG (Ponatinib) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

ICLUSIG (ponatinib) is a tyrosine kinase inhibitor approved for specific adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its market trajectory is shaped by clinical efficacy, regulatory scrutiny, patent landscape, and competition.

What is the Clinical Indication and Efficacy of ICLUSIG?

ICLUSIG is indicated for adults with CML, including chronic phase, accelerated phase, or blast phase, who are resistant or intolerant to at least two prior tyrosine kinase inhibitors (TKIs). It is also approved for adults with Ph+ ALL who are resistant or intolerant to prior TKI therapy. The drug targets BCR-ABL1, including mutations resistant to other TKIs like T315I.

Clinical trials demonstrate significant response rates in heavily pre-treated patient populations. For instance, in the PACE trial, 31% of patients with chronic phase CML resistant to two or more TKIs achieved a major cytogenetic response (MCyR) with ponatinib. In accelerated phase CML, MCyR was achieved by 27% of patients. [1] For blast phase CML and Ph+ ALL, response rates were lower but still represented a therapeutic option for patients with limited alternatives. [1]

What is the Regulatory Status and History of ICLUSIG?

ICLUSIG received accelerated approval from the U.S. Food and Drug Administration (FDA) in December 2012. [2] This approval was contingent on a confirmatory trial to verify clinical benefit. Following reports of serious and fatal vascular occlusive events, the FDA, in collaboration with ARIAD Pharmaceuticals (now part of Takeda), Voluntarily initiated a Risk Evaluation and Mitigation Strategy (REMS) program and later placed a temporary halt on sales in October 2013. [3]

The drug was reintroduced to the market in April 2014 with updated prescribing information, including a boxed warning regarding the risks of arterial and venous thrombosis and occlusions. [3] The updated label reflected a revised recommended starting dose from 45 mg once daily to 30 mg once daily, with dose adjustments based on response and tolerability. [3] The confirmatory trial, which continued enrollment post-launch, was designed to further assess the benefit-risk profile.

In July 2018, the FDA approved the supplemental New Drug Application (sNDA) for ICLUSIG based on updated data from the PACE trial, which demonstrated substantial and sustained efficacy in the approved indications, particularly in patients with the T315I mutation. [4] The FDA concluded that the benefits of ICLUSIG outweigh its risks for the specified patient populations.

What is the Patent Landscape for ICLUSIG?

The patent landscape for ponatinib is critical for its market exclusivity. Takeda Pharmaceutical Company holds key patents related to ponatinib.

• U.S. Patent No. 8,114,990: This patent, filed in 2009 and issued in 2012, covers methods of treating CML and Ph+ ALL. [5]
• U.S. Patent No. 9,266,850: This patent, issued in 2016, is directed to specific crystalline forms of ponatinib. [6]
• U.S. Patent No. 9,901,547: Issued in 2018, this patent claims specific polymorphic forms and pharmaceutical compositions of ponatinib. [7]

These patents, along with others covering formulation and manufacturing processes, provide market protection for Takeda. The earliest anticipated expiration for a core patent related to the composition of matter for ponatinib is generally around 2027-2030, factoring in patent term extensions and potential adjustments. Generic entry would typically commence after the expiration of all relevant and enforceable patents.

What are the Key Market Drivers and Challenges for ICLUSIG?

Market Drivers:

• Unmet Need in Resistant/Intolerant Patients: ICLUSIG addresses a critical unmet need for patients with CML and Ph+ ALL who have failed multiple prior TKI therapies, particularly those with the T315I mutation, which confers resistance to many other TKIs.
• Superior Efficacy Against T315I Mutation: Ponatinib is one of the few agents demonstrating significant activity against the T315I mutation, a major mechanism of resistance in CML.
• Confirmation of Benefit: The regulatory pathway, including confirmatory trials and subsequent FDA approval based on demonstrated efficacy, solidified its position as a valuable treatment option.

Market Challenges:

• Safety Profile and Black Box Warnings: The serious risk of vascular occlusive events necessitates careful patient selection, monitoring, and dose management, impacting physician prescribing patterns and patient accessibility.
• Competition: While ICLUSIG targets a specific niche, the broader CML and Ph+ ALL market has seen the development of multiple TKIs with varying efficacy and safety profiles. Newer generation TKIs and other therapeutic modalities continue to emerge.
• High Cost of Therapy: Like many targeted oncology therapies, ICLUSIG carries a significant acquisition cost, which can influence formulary access and patient out-of-pocket expenses.
• Navigating REMS Program: Adherence to the REMS program requirements adds complexity to prescribing and dispensing.

What is the Competitive Landscape for ICLUSIG?

The competitive landscape for ICLUSIG is defined by other TKIs used in CML and Ph+ ALL treatment pathways.

• First-generation TKIs: Imatinib (Gleevec), Nilotinib (Tasigna), Dasatinib (Sprycel), Bosutinib (Bosulif). These are often used earlier in treatment and may be ineffective in patients who develop resistance mutations like T315I.
• Third-generation TKIs: Asciminib (Scemblix) is a notable competitor, approved for CML patients previously treated with two or more TKIs who are intolerant or resistant, and for those with the T315I mutation. [8] Asciminib represents a direct competitor in the T315I space with a different mechanism of action (STAMP inhibitor).
• Other Therapies: Allogeneic stem cell transplantation remains a curative option for some patients, and investigational therapies are continually being developed.

ICLUSIG's key differentiator remains its proven efficacy against the T315I mutation, a profile shared by asciminib. However, the specific patient population benefiting from each drug, their respective safety profiles, and treatment guidelines influence physician choice.

What is the Financial Trajectory and Market Size of ICLUSIG?

The financial trajectory of ICLUSIG is influenced by its niche indication, pricing, and sales volume. Detailed, up-to-the-minute financial data is proprietary to Takeda. However, publicly available reports and analyst estimates provide insights.

• Revenue: Following its reintroduction in 2014, ICLUSIG's sales have shown a steady, albeit moderate, growth. For instance, in 2020, net sales of ICLUSIG were approximately $517 million. [9] In 2022, net sales increased to around $620 million. [10]
• Pricing: The list price for ICLUSIG is significant, reflecting its targeted indication and R&D investment. A 30-day supply can range from approximately $15,000 to $20,000 USD, depending on the dosage. [11]
• Market Size: The addressable market for ICLUSIG is defined by the incidence and prevalence of CML and Ph+ ALL patients who have exhausted other TKI options, especially those with the T315I mutation. Estimates for the global CML market vary, but the segment requiring third-line or later therapy, particularly with resistance mutations, represents a focused sub-market. The emergence of direct competitors like asciminib will influence the future market share.

The financial trajectory will be sustained by the continued need for effective therapies in this difficult-to-treat patient segment. However, patent expiry and the introduction of generics in the future will mark a significant shift in its financial outlook.

Key Takeaways

• ICLUSIG is a critical therapy for CML and Ph+ ALL patients resistant to prior TKIs, especially those with the T315I mutation.
• Its regulatory history reflects a careful balance between significant efficacy and serious safety concerns, managed through a robust REMS program and updated labeling.
• Core patent protection is anticipated to extend into the late 2020s, delaying generic competition.
• Market drivers include high unmet need and efficacy against resistant mutations, while challenges arise from its safety profile, competition, and cost.
• Recent financial performance shows consistent revenue growth, underscoring its value in its niche.

FAQs

1. When is generic ICLUSIG expected to be available? Generic availability for ICLUSIG is contingent upon the expiration of all relevant patents, including any potential patent term extensions. Based on current patent filings, generic entry is generally anticipated in the late 2020s, subject to litigation outcomes and regulatory approvals.

2. How does ICLUSIG's safety profile compare to other third-generation TKIs like asciminib? ICLUSIG carries a boxed warning for arterial and venous thrombosis and occlusions. Asciminib, while also having potential side effects, has a different safety profile with its own set of warnings, including warnings for cardiovascular events and gastrointestinal issues. Direct comparative clinical trials are limited, and treatment decisions often depend on individual patient profiles and physician preference based on known risk-benefit analyses.

3. What is the typical duration of treatment with ICLUSIG? Treatment with ICLUSIG is generally considered a long-term or indefinite therapy for patients who achieve and maintain a response and tolerate the drug. Discontinuation is typically considered in cases of unacceptable toxicity or loss of response.

4. What specific TKI resistance mutations does ICLUSIG target effectively? ICLUSIG is specifically indicated and shows significant efficacy against the T315I mutation in BCR-ABL1, a key mutation that confers resistance to many other TKIs like imatinib, nilotinib, and dasatinib.

5. What is the estimated annual cost of therapy for ICLUSIG? The annual cost of therapy for ICLUSIG can range significantly based on dosage, insurance coverage, and patient assistance programs. However, based on a monthly list price of $15,000-$20,000, the gross annual cost can exceed $180,000-$240,000 USD before any discounts or rebates.

Citations

[1] Cortes, J. E., Hochhaus, A., Gambacorti-Passerini, C., Hughes, T. P., Larson, R. A., Druker, H., ... & Radich, J. P. (2013). Efficacy and tolerability of ponatinib in patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to prior tyrosine kinase inhibitors. Blood, 122(7), 1361-1371.

[2] U.S. Food and Drug Administration. (2012, December 14). FDA approves Iclusig (ponatinib) to treat certain types of leukemia. [Press Release].

[3] U.S. Food and Drug Administration. (2014, April 28). FDA approves Iclusig (ponatinib) with revised prescribing information to treat certain types of leukemia. [Press Release].

[4] Takeda Pharmaceutical Company Limited. (2018, July 26). Takeda Announces U.S. FDA Approval of ICLUSIG® (ponatinib) for Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). [Press Release].

[5] U.S. Patent No. 8,114,990 B2. (2012). Methods of treating Philadelphia chromosome positive leukemias. Assignee: Ariad Pharmaceuticals, Inc.

[6] U.S. Patent No. 9,266,850 B2. (2016). Polymorphic forms of ponatinib. Assignee: Ariad Pharmaceuticals, Inc.

[7] U.S. Patent No. 9,901,547 B2. (2018). Polymorphic forms of ponatinib and pharmaceutical compositions thereof. Assignee: Ariad Pharmaceuticals, Inc.

[8] U.S. Food and Drug Administration. (2021, December 17). FDA approves asciminib for chronic myeloid leukemia. [Press Release].

[9] Takeda Pharmaceutical Company Limited. (2021). Takeda Reports Full-Year FY2020 Results. [Financial Report].

[10] Takeda Pharmaceutical Company Limited. (2023). Takeda Reports Full-Year FY2022 Results. [Financial Report].

[11] Drug pricing data obtained from various healthcare cost databases and pharmacy benefit manager resources, reflecting list prices before patient assistance or negotiated discounts.